Medical Education: Jeanine M. Walenga, PhD | Loyola Medicine

COVID-19 (Coronavirus) Update

Loyola Medicine is resuming select health care services. Learn more about resumption of services.

Jeanine M. Walenga, PhD

Thoracic and Cardiovascular Surgery

Professor
Associate Director, Point of Care Testing,Medical Director, Clinical Coagulation Lab/Urinalysis Lab

Languages Spoken

English

Clinical Expertise

Biography

Interests

Medical Education

Medical School
Residency
Fellowship

Board Certification

Research

  • Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device McClane, N.; Jeske, W.; Walenga, J. M.; Escalante, V.; Hoppensteadt, D.; Schwartz, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. Ramacciotti, E; Castelli, V; Walenga, J; Fareed, J, International angiology : a journal of the International Union of Angiology
  • Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes. Prechel, M; Hudec, S; Lowden, E; Escalante, V; Emanuele, N; Emanuele, M; Walenga, JM, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
View All ResearchShow Less
  • Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices Jeske, W. P.; Walenga, J. M.; Menapace, B.; Schwartz, J.; Bakhos, M., Biomarkers in medicine
  • Measurement of dabigatran rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study., Harenberg, J; Du, S; Wehling, M; Zolfaghari, S; Weiss, C; Kr?mer, R; Walenga, J, Clinical chemistry and laboratory medicine
  • North American Thrombosis Forum AF Action Initiative Consensus Document, Ruff, C. T.; Ansell, J. E.; Becker, R. C.; Benjamin, E. J.; Deicicchi, D. J.; Mark Estes, N. A.; Ezekowitz, M. D.; Fanikos, J.; Fareed, J.; Garcia, D.; Giugliano, R. P.; Goldhaber, S. Z.; Granger, C.; Healey, J. S.; Hull, R.; Hylek, E. M.; Libby, P.; Lopes, R. D.; Mahaffey, K. W.; Mega, J.; Piazza, G.; Sasahara, A. A.; Sorond, F. A.; Spyropoulos, A. C.; Walenga, J. M.; Weitz, J. I., The American Journal of Medicine
  • Sulodexide for the extended treatment of venous thromboembolism Walenga, J. M.; Fareed, J.; Ramacciotti, E., International angiology : a journal of the International Union of Angiology
  • Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay Gerotziafas, G. T.; Rouseau, A.; Mbemba, E.; Khartechi, A.; Dreden, P. V.; Walenga, J.; Fareed, J.; Elalamy, I., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Complexes of platelet factor 4 and heparin activate Toll-like receptor 4 Prechel, M. M.; Walenga, J. M., Journal of thrombosis and haemostasis : JTH
  • Production of Anti-platelet Factor 4/Heparin Complex Antibodies After Cardiovascular Surgery Matsuo, T.; Motohashi, S.; Wanaka, K.; Walenga, J. M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Anticoagulant and Antithrombotic Actions of AVE5026 an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin, Hoppensteadt, D. A.; Gray, A.; Jeske, W. P.; Walenga, J. M.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Sustained release of tissue factor following thrombosis of lower limb trauma Walenga, J. M.; Kaiser, P. C.; Prechel, M. M.; Hoppensteadt, D.; Jeske, W. P.; Misselwitz, F.; Bacher, P.; Lassen, M. R.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Hoppensteadt, D.; Escalante, V.; Chaudhry, T.; Jeske, W. P.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative studies on branded enoxaparin and a US generic version of enoxaparin Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Cunanan, J.; Khan, H.; Escalante, V.; Fareed, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Emphasis on the Role of PF4 in the Incidence Pathophysiology and Treatment of Heparin Induced Thrombocytopenia, Prechel, M. M.; Walenga, J. M., Thrombosis journal
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer Walenga, J. M.; Lyman, G. H., Critical reviews in oncology/hematology
  • Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction Govindan, S.; Kuster, D. W.; Lin, B.; Kahn, D. J.; Jeske, W. P.; Walenga, J. M.; Leya, F.; Hoppensteadt, D.; Fareed, J.; Sadayappan, S., American journal of cardiovascular disease
  • Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen Ashbrook, M.; Walenga, J. M.; Schwartz, J.; Heroux, A.; Jeske, W. P.; Escalante, V.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Prothrombin fragment 1.2 and modified antithrombin as predictors of disseminated intravascular coagulation and thrombotic risk in thermal injury Kowal-Vern, A.; Walenga, J. M.; Hoppensteadt, D.; Gamelli, R. L., Journal of burn care & research : official publication of the American Burn Association
  • A colorimetric metabolic dye reduction assay detects highly activated platelets: application in the diagnosis of heparin-induced thrombocytopenia., Prechel, M. M.; Escalante, V.; Drenth, A. F.; Walenga, J. M., Platelets
  • Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins Walenga, J. M.; Jeske, W. P.; Escalante, V.; Hoppensteadt, D.; Fareed, J.; Bakhos, M., International angiology : a journal of the International Union of Angiology
  • A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H.; Viskov, C., Thrombosis research
  • An open label non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers., Gomes, M.; Ramacciotti, E.; Hoppensteadt, D.; Walenga, J. M.; Lewis, B.; Thethi, I.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Jeske, W. P.; Walenga, J. M.; Samama, M. M.; Hoppensteadt, D.; Mayuga, M.; Fareed, J., Blood Coagulation & Fibrinolysis
  • Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Walenga, J. M.; Jackson, C. M.; Kessler, C. M., Seminars in Thrombosis & Hemostasis
  • Simple scoring system for early management of heparin-induced thrombocytopenia. Messmore, H. L.; Fabbrini, N.; Bird, M. L.; Choudhury, A. M.; Cerejo, M.; Prechel, M.; Jeske, W. P.; Siddiqui, A.; Thethi, I.; Wehrmacher, W. H.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • A consensus conference on complex biologics and low molecular weight heparin Kalodiki, E.; Fareed, J.; Tapson, W. F.; Hoppensteadt, D. A.; Carter, C. A.; Sussman, I.; Parker, S.; Harenberg, J.; Hull, R.; Rao, G.; Lovinger, D. F.; Reid, L. D.; Kakkar, A.; Talarico, L.; Ofosu, F. A.; Bussey, H. I.; Fanikos, J.; Groce, J. B.; Skinner, N.; Ahluwalia, M.; Iqbal, O.; Jackson, C. M.; Jeske, W. P.; Ramacciotti, E.; Van Thiel, D.; Wahi, R.; Walenga, J., International Angiology
  • Drug and dietary interactions of the new and emerging oral anticoagulants Walenga, J. M.; Adiguzel, C., International journal of clinical practice
  • In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative Kuziej, J.; Litinas, E.; Hoppensteadt, D. A.; Liu, D.; Walenga, J. M.; Fareed, J.; Jeske, W., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Laboratory methods and management of patients with heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Biology
  • Low anticoagulant heparin targets multiple sites of inflammation suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands., Rao, N. V.; Argyle, B.; Xu, X.; Reynolds, P. R.; Walenga, J. M.; Prechel, M.; Prestwich, G. D.; MacArthur, R. B.; Walters, B. B.; Hoidal, J. R.; Kennedy, T. P., American Journal of Physiology - Cell Physiology
  • Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia. Prechel, M. M.; Jeske, W. P.; Walenga, J. M., Thrombosis research
  • Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes. Diaz, J.; Prechel, M.; Emanuele, M.; Emanuele, N.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. Montalescot, G.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He, Z.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. Gluckman, T. J.; Segal, J. B.; Schulman, S. P.; Shapiro, E. P.; Kickler, T. S.; Prechel, M. M.; Conte, J. V.; Walenga, J. M.; Shafique, I.; Rade, J. J., Journal of Thrombosis & Haemostasis
  • Effectiveness of a clinical decision support system to identify heparin induced thrombocytopenia. Riggio, J. M.; Cooper, M. K.; Leiby, B. E.; Walenga, J. M.; Merli, G. J.; Gottlieb, J. E., Journal of Thrombosis & Thrombolysis
  • Heparin-induced thrombocytopenia: controversies and updates Walenga, J. M., eThrombosis Online Newsletter
  • Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Viskov, C.; Bouley, E.; Hubert, P.; Martinez, C.; Herman, F.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel, C.; Jeske, W. P.; Hoppensteadt, D.; Walenga, J. M.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • A tribute to Professor Hans Klaus Breddin Fareed, J.; Walenga, J. M., Seminars in Thrombosis and Hemostasis
  • Antigenic (immunogenic) profiling of bovine thrombin and its purified forms. Walenga, J. M.; Bick, R. L.; Messmore, H. L., Clinical & Applied Thrombosis/Hemostasis
  • Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Fareed, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Prechel, M.; Iqbal, O.; Adiguzel, C.; Clark, M.; Litinas, E.; cunanan, J.; Linhardt, R.; Harenberg, J., Seminars in thrombosis and hemostatis
  • Differentiating low-molecular-weight heparins based on chemical biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins, Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Vandenberg, C.; Brubaker, A.; Adiguzel, C.; Bakhos, M.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Dr. Eberhard F. Mammen remembered. A great clinician-scientist mentor, and friend., Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Bick, R. L.; Messmore, H. L., Seminars in Thrombosis and Hemostasis
  • Heparin-induced thrombocytopenia: a serious complication of heparin therapy for acute stroke. Kawano, H.; Toyoda, K.; Miyata, S.; Yamamoto, H.; Okamoto, A.; Kakutani, I.; Walenga, J. M.; Naritomi, H.; Minematsu, K., Cerebrovascular Diseases
  • Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Untch, B. R.; Jeske, W. P.; Schwartz, J.; Botkin, S.; Prechel, M.; Walenga, J. M.; Bakhos, M., Clinical & Applied Thrombosis/Hemostasis
  • Landmarks in anti-thrombin drug development: the argatroban story. Walenga, J. M.; Bounameaux, H.; Ikeda, Y., Seminars in Thrombosis and Hemostasis
  • Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Clark, M.; Hoppensteadt, D.; Walenga, J. M.; Myers, L.; Cunanan, J.; Jeske, W.; Adiguzel, C.; Iqbal, O.; Fareed, J., International Angiology
  • Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Adiguzel, C.; Iqbal, O.; Cunanan, J.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Rivaroxaban--an oral direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia., Walenga, J. M.; Prechel, M.; Jeske, W. P.; Hoppensteadt, D.; Maddineni, J.; Iqbal, O.; Messmore, H. L.; Bakhos, M., British journal of haematology
  • The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Bick, R. L.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • The future of anticoagulation Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Fareed, J., Seminars in Respiratory & Critical Care Medicine
  • The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update Prechel, M.; Walenga, J. M., Seminars in Thrombosis & Hemostasis
  • The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia Hoppensteadt, D. A.; Walenga, J. M., Hematology - Oncology Clinics of North America
  • Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Walenga, J. M.; Drenth, A. F.; Mayuga, M.; Hoppensteadt, D. A.; Prechel, M.; Harder, S.; Watanabe, H.; Osakabe, M.; Breddin, H. K., Clinical & Applied Thrombosis/Hemostasis
  • Heparin oligosaccharides as potential therapeutic agents in senile dementia Ma, Q.; Cornelli, U.; Hanin, I.; Jeske, W. P.; Linhardt, R. J.; Walenga, J. M.; Fareed, J.; Lee, J. M., Current pharmaceutical design
  • Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Demir, M.; Duran, E.; Yigitbasi, O.; Vural, O.; Kurum, T.; Yuksel, M.; Turgut, B.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Isolation and characterization of heparin from tuna skins. Jeske, W. P.; McDonald, M. K.; Hoppensteadt, D. A.; Bau, E. C.; Mendes, A.; Dietrich, C. P.; Walenga, J. M.; Coyne, E., Clinical & Applied Thrombosis/Hemostasis
  • Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Ma, Q.; Tobu, M.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Walenga, J. M.; Cornelli, U.; Lee, J.; Linhardt, R.; Hanin, I.; Fareed, J., Thrombosis research
  • Non-anticoagulant effects of unfractionated and low-molecular weight heparins. Walenga, J. M., Clinical Advances in Hematology & Oncology
  • Why differentiate low molecular weight heparins for venous thromboembolism?. Fareed, J.; Walenga, J. M., Thrombosis Journal [Electronic Resource]
  • Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Walenga, J. M., International Angiology
  • Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications Maddineni, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D. A.; Fareed, J.; Wahi, R.; Bick, R. L., Clinical & Applied Thrombosis/Hemostasis
  • Update on the clinical applications of argatroban. Fareed, J.; Jeske, W. P.; Hoppensteadt, D. A.; Walenga, J. M., Future Cardiology
  • Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. Prechel, M. M.; McDonald, M. K.; Jeske, W. P.; Messmore, H. L.; Walenga, J. M., Journal of Thrombosis & Haemostasis
  • Development of generic low molecular weight heparins: a perspective Fareed, J.; Leong, W.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Short- and long-acting synthetic pentasaccharides as antithrombotic agents Walenga, J. M.; Jeske, W. P.; Fareed, J., Expert opinion on investigational drugs
  • Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Iqbal, O.; Tobu, M.; Aziz, S.; Gerdisch, M.; Da Valle, M.; Demir, M.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Fareed, J., Journal of cardiac surgery
  • Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Jeske, W. P.; Bakhos, M., Current opinion in pulmonary medicine
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Argatroban use during pediatric interventional cardiac catheterization. Cetta, F.; Graham, L. C.; Wrona, L. L.; Arruda, M. J.; Walenga, J. M., Catheterization & Cardiovascular Interventions
  • Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bacher, P.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Ahmad, S.; Untch, B.; Haas, S.; Hoppensteadt, D. A.; Misselwitz, F.; Messmore, H. L.; Walenga, J. M.; Fareed, J., Molecular & Cellular Biochemistry
  • Factor Xa inhibitors Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Methods in Molecular Medicine
  • Generic low-molecular-weight heparins: some practical considerations Fareed, J.; Leong, W. L.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Wahi, R.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Laboratory methods for heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Monitoring the new antithrombotic drugs.[erratum appears in Semin Thromb Hemost. 2005 Apr;31(2):247] Walenga, J. M.; Hoppensteadt, D. A., Seminars in Thrombosis & Hemostasis
  • Newer insights on the mechanism of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Benefit-risk assessment of treatments for heparin-induced thrombocytopenia Messmore, H.; Jeske, W.; Wehrmacher, W.; Walenga, J. M., Drug Safety
  • Factor Xa inhibitors: today and beyond Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Current Opinion in Investigational Drugs
  • Heparin low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation, Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases. Porcelli, R.; Moskowitz, B. C.; Cetta, F.; Graham, L. C.; Godwin, J. E.; Eidem, B. W.; Prechel, M. M.; Walenga, J. M., Texas Heart Institute Journal
  • Heparin-induced thrombocytopenia paradoxical thromboembolism, and other adverse effects of heparin-type therapy, Walenga, J. M.; Frenkel, E. P.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T., Clinical pharmacokinetics
  • Emerging anticoagulant and thrombolytic drugs Iqbal, O.; Aziz, S.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Bakhos, M.; Fareed, J., Expert opinion on emerging drugs
  • Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test Wallock, M.; Jeske, W. P.; Bakhos, M.; Walenga, J. M., Perfusion
  • The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Kowal-Vern, A.; Walenga, J. M.; McGill, V.; Gamelli, R. L., Burns
  • Antithrombin III concentrate in the acute phase of thermal injury. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L., Burns
  • Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L., Journal of Burn Care & Rehabilitation
  • Bleeding complications with glycoprotein IIb/IIIa inhibitors Iqbal, O.; Walenga, J. M.; Lewis, B. E.; Bakhos, M., Drugs of today (Barcelona, Spain : 1998)